Top

Published in:

01-07-2013 | Review Article

Animal model for mammary tumor growth in the bone microenvironment

Authors: Mitsuru Futakuchi, Rakesh K. Singh

Published in: Breast Cancer | Issue 3/2013

Abstract

Advanced breast cancer commonly spreads to the bones, lungs, liver or brain, and bone is the most common site of breast cancer metastasis. Nearly all patients with advanced breast cancer develop bone metastasis and suffer from serious bone metastasis-associated complications, including chronic pain, fracture, spinal cord compression and hypercalcemia. Metastasis formation in the bone is a complex process that requires cooperative reciprocal interactions between tumor cells and the cellular environment of the bone, which includes osteoclasts and osteoblasts. We have developed a murine bone invasion model of breast cancer, which required a simple surgical technique and mimics the biology of the disease. Osteolytic and/or osteoblastic lesions induced in the tumor-bone interface allowed us to explore cellular and molecular interactions between malignant cells and skeletal tissue in a syngeneic setting. In this review, we will discuss a different animal model that provides a consistent and reproducible platform for investigating the molecular mechanisms underlying tumor–bone interaction and breast cancer-induced osteolytic changes.

Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2012;42:139–47. doi:10.1093/jjco/hyr184.CrossRefPubMed

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29. doi:10.3322/caac.20138.CrossRefPubMed

Yi M, Liu P, Li X, Mittendorf EA, He J, Ren Y, Nayeemuddin K, Hunt KK. Comparative analysis of clinicopathologic features, treatment, and survival of Asian women with a breast cancer diagnosis residing in the United States. Cancer. 2012;118:4117–25. doi:10.1002/cncr.27399.CrossRefPubMed

Yip CH, Smith RA, Anderson BO, Miller AB, Thomas DB, Ang ES, Caffarella RS, Corbex M, Kreps GL, McTiernan A. Guideline implementation for breast healthcare in low- and middle-income countries: early detection resource allocation. Cancer. 2008;113:2244–56. doi:10.1002/cncr.23842.CrossRefPubMed

Jensen AO, Jacobsen JB, Norgaard M, Yong M, Fryzek JP, Sorensen HT. Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer. 2011;11:29. doi:10.1186/1471-2407-11-29.CrossRefPubMed

Coleman RE. Future directions in the treatment and prevention of bone metastases. Am J clin oncol. 2002;25:S32–8.CrossRefPubMed

Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61–6.CrossRefPubMed

Diel IJ, Solomayer EF, Bastert G. Treatment of metastatic bone disease in breast cancer: bisphosphonates. Clin Breast Cancer. 2000;1:43–51.CrossRefPubMed

Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damiao R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gomez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379:39–46. doi:10.1016/S0140-6736(11)61226-9.CrossRefPubMed

10.

Barton MK. Denosumab an option for patients with bone metastasis from breast cancer. CA Cancer J Clin. 2011;61:135–6. doi:10.3322/caac.20116.CrossRefPubMed

11.

Charhon SA, Chapuy MC, Delvin EE, Valentin-Opran A, Edouard CM, Meunier PJ. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer. 1983;51:918–24.CrossRefPubMed

12.

Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584–93. doi:10.1038/nrc867nrc867.CrossRefPubMed

13.

Leibbrandt A, Penninger JM. RANKL/RANK as key factors for osteoclast development and bone loss in arthropathies. Adv Exp Med Biol. 2009;649:100–13.CrossRefPubMed

14.

Delaisse JM, Andersen TL, Engsig MT, Henriksen K, Troen T, Blavier L. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc Res Tech. 2003;61:504–13. doi:10.1002/jemt.10374.CrossRefPubMed

15.

Guo B, Villeneuve DJ, Hembruff SL, Kirwan AF, Blais DE, Bonin M, Parissenti AM. Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Breast Cancer Res Treat. 2004;85:31–51. doi:10.1023/B:BREA.0000021046.29834.12.CrossRefPubMed

16.

Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3:537–49.CrossRefPubMed

17.

Kuperwasser C, Dessain S, Bierbaum BE, Garnet D, Sperandio K, Gauvin GP, Naber SP, Weinberg RA, Rosenblatt M. A mouse model of human breast cancer metastasis to human bone. Cancer Res. 2005;65:6130–8. doi:10.1158/0008-5472.can-04-1408.CrossRefPubMed

18.

Murphy BO, Joshi S, Kessinger A, Reed E, Sharp JG. A murine model of bone marrow micrometastasis in breast cancer. Clin Exp Metastasis. 2002;19:561–9.CrossRefPubMed

19.

Nemeth JA, Harb JF, Barroso U Jr, He Z, Grignon DJ, Cher ML. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res. 1999;59:1987–93.PubMed

20.

Reddi AH, Roodman D, Freeman C, Mohla S. Mechanisms of tumor metastasis to the bone: challenges and opportunities. J Bone Miner Res. 2003;18:190–4. doi:10.1359/jbmr.2003.18.2.190.CrossRefPubMed

21.

Shtivelman E, Namikawa R. Species-specific metastasis of human tumor cells in the severe combined immunodeficiency mouse engrafted with human tissue. Proc Natl Acad Sci USA. 1995;92:4661–5.CrossRefPubMed

22.

Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun. 2005;328:679–87. doi:10.1016/j.bbrc.2004.11.070.CrossRefPubMed

23.

Hiraga T, Ueda A, Tamura D, Hata K, Ikeda F, Williams PJ, Yoneda T. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Int J cancer. 2003;106:973–9. doi:10.1002/ijc.11330.CrossRefPubMed

24.

Iguchi H, Tanaka S, Ozawa Y, Kashiwakuma T, Kimura T, Hiraga T, Ozawa H, Kono A. An experimental model of bone metastasis by human lung cancer cells: the role of parathyroid hormone-related protein in bone metastasis. Cancer Res. 1996;56:4040–3.PubMed

25.

Zhu L, Loo WT, Chow LW. Circulating tumor cells in patients with breast cancer: possible predictor of micro-metastasis in bone marrow but not in sentinel lymph nodes. Biomed Pharmacother 2005; 59 Suppl 2: S355–8.

26.

Abramson VG, Mayer IA. Clinical utility of serum tumor markers and circulating tumor cell assays in the treatment of breast cancer. Curr Treat Options Oncol. 2011;12:403–11. doi:10.1007/s11864-011-0164-2.CrossRefPubMed

27.

Reyal F, Valet F, de Cremoux P, Mathiot C, Decraene C, Asselain B, Brain E, Delaloge S, Giacchetti S, Marty M, Pierga JY, Bidard FC. Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients. Ann Oncol Off J European Soc Med Oncol/ESMO. 2011;22:1458–9. doi:10.1093/annonc/mdr144.CrossRef

28.

Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8:98–101.PubMed

29.

Patel SA, Dave MA, Murthy RG, Helmy KY, Rameshwar P. Metastatic breast cancer cells in the bone marrow microenvironment: novel insights into oncoprotection. Oncol Rev. 2011;5:93–102. doi:10.1007/s12156-010-0071-y.CrossRefPubMed

30.

Siclari VA, Guise TA, Chirgwin JM. Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev. 2006;25:621–33. doi:10.1007/s10555-006-9023-1.CrossRefPubMed

31.

Luis-Ravelo D, Anton I, Vicent S, Hernandez I, Valencia K, Zandueta C, Martinez-Canarias S, Gurpide A, Lecanda F. Tumor-stromal interactions of the bone microenvironment: in vitro findings and potential in vivo relevance in metastatic lung cancer models. Clin Exp Metastasis. 2011;28:779–91. doi:10.1007/s10585-011-9409-5.CrossRefPubMed

32.

Sosnoski DM, Krishnan V, Kraemer WJ, Dunn-Lewis C, Mastro AM. Changes in cytokines of the bone microenvironment during breast cancer metastasis. Int J Breast cancer. 2012;2012:160265. doi:10.1155/2012/160265.PubMed

33.

Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK, Vargo-Gogola TC, Begtrup JL, Peterson TE, Fingleton B, Shirai T, Matrisian LM, Futakuchi M. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell. 2005;7:485–96.CrossRefPubMed

34.

Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992;52:1399–405.PubMed

35.

Huang X, Wong MK, Yi H, Watkins S, Laird AD, Wolf SF, Gorelik E. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res. 2002;62:5727–35.PubMed

36.

Sloan EK, Stanley KL, Anderson RL. Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene. 2004;23:7893–7. doi:10.1038/sj.onc.1208062.CrossRefPubMed

37.

Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, Anderson RL. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis. 1999;17:163–70.CrossRefPubMed

38.

Heppner GH, Miller FR, Shekhar PM. Nontransgenic models of breast cancer. Breast cancer Res BCR. 2000;2:331–4.CrossRef

39.

Kakonen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer. 2003;97:834–9. doi:10.1002/cncr.11132.CrossRefPubMed

40.

Hiraga T, Myoui A, Choi ME, Yoshikawa H, Yoneda T. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006;66:2067–73. doi:10.1158/0008-5472.can-05-2012.CrossRefPubMed

41.

Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006;12:6213s–6s. doi:10.1158/1078-0432.ccr-06-1007.CrossRefPubMed

42.

Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, Grubbs BG, Dallas M, Cui Y, Guise TA. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem. 2002;277:24571–8. doi:10.1074/jbc.M202561200.CrossRefPubMed

43.

Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6:506–20. doi:10.1038/nrc1926.CrossRefPubMed

44.

Oft M, Heider KH, Beug H. TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol CB. 1998;8:1243–52.CrossRef

45.

Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 1996;10:2462–77.CrossRefPubMed

46.

Bierie B, Stover DG, Abel TW, Chytil A, Gorska AE, Aakre M, Forrester E, Yang L, Wagner KU, Moses HL. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res. 2008;68:1809–19. doi:10.1158/0008-5472.can-07-5597.CrossRefPubMed

47.

Massague J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67:753–91. doi:10.1146/annurev.biochem.67.1.753.CrossRefPubMed

48.

Massague J, Gomis RR. The logic of TGFbeta signaling. FEBS Lett. 2006;580:2811–20. doi:10.1016/j.febslet.2006.04.033.CrossRefPubMed

49.

Futakuchi M, Nannuru KC, Varney ML, Sadanandam A, Nakao K, Asai K, Shirai T, Sato SY, Singh RK. Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation. Cancer Sci. 2009;100:71–81. doi:10.1111/j.1349-7006.2008.01012.x.CrossRefPubMed

50.

Warwick-Davies J, Lowrie DB, Cole PJ. Selective deactivation of human monocyte functions by TGF-beta. J Immun. 1995;155:3186–93.PubMed

51.

Fuller K, Lean JM, Bayley KE, Wani MR, Chambers TJ. A role for TGFbeta(1) in osteoclast differentiation and survival. J Cell Sci. 2000;113(Pt 13):2445–53.PubMed

52.

Sells Galvin RJ, Gatlin CL, Horn JW, Fuson TR. TGF-beta enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF. Biochem Biophys Res Commun. 1999;265:233–9. doi:10.1006/bbrc.1999.1632.CrossRefPubMed

53.

Fox SW, Haque SJ, Lovibond AC, Chambers TJ. The possible role of TGF-beta-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. J Immunol (Baltimore, Md.: 1950) 2003; 170: 3679–3687.

54.

Guise TA, Chirgwin JM. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin Orthop Relat Res 2003; S32–38. doi : 10.1097/01.blo.0000093055.96273.69.

55.

Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM, Cornell JE, Pollock BH, Mundy GR, Sun LZ. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res. 2006;66:6714–21. doi:10.1158/0008-5472.can-05-3565.CrossRefPubMed

56.

Sato S, Futakuchi M, Ogawa K, Asamoto M, Nakao K, Asai K, Shirai T. Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment. Cancer Sci. 2008;99:316–23. doi:10.1111/j.1349-7006.2007.00690.x.CrossRefPubMed

57.

Ohshiba T, Miyaura C, Inada M, Ito A. Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis. Br J Cancer. 2003;88:1318–26. doi:10.1038/sj.bjc.6600858.CrossRefPubMed

58.

Jimi E, Aoki K, Saito H, D’Acquisto F, May MJ, Nakamura I, Sudo T, Kojima T, Okamoto F, Fukushima H, Okabe K, Ohya K, Ghosh S. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med. 2004;10:617–24. doi:10.1038/nm1054.CrossRefPubMed

59.

Wilson TJ, Nannuru KC, Futakuchi M, Sadanandam A, Singh RK. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand. Cancer Res. 2008;68:5803–11. doi:10.1158/0008-5472.CAN-07-5889.CrossRefPubMed

60.

Selak MA, Chignard M, Smith JB. Cathepsin G is a strong platelet agonist released by neutrophils. Biochem J. 1988;251:293–9.PubMed

61.

Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 2000;103:41–50.CrossRefPubMed

62.

Cao Y, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV, Karin M. IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell. 2001;107:763–75.CrossRefPubMed

63.

Cao Y, Luo JL, Karin M. IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci USA. 2007;104:15852–7. doi:10.1073/pnas.0706728104.CrossRefPubMed

64.

Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh DA, Karin M. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature. 2007;446:690–4. doi:10.1038/nature05656.CrossRefPubMed

65.

Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 2011;470:548–53. doi:10.1038/nature09707.CrossRefPubMed

66.

Sadanandam A, Futakuchi M, Lyssiotis CA, Gibb WJ, Singh RK. A cross-species analysis of a mouse model of breast cancer-specific osteolysis and human bone metastases using gene expression profiling. BMC Cancer. 2011;11:304. doi:10.1186/1471-2407-11-304.CrossRefPubMed

Title: Animal model for mammary tumor growth in the bone microenvironment
Authors: Mitsuru Futakuchi
Rakesh K. Singh
Publication date: 01-07-2013
Publisher: Springer Japan
Published in: Breast Cancer / Issue 3/2013
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-013-0439-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2013

Reply to Ozkan et al.: a role of elastography using maximum fat-to-lesion ratio for the diagnosis of breast lesions

Influence of the in situ component in 389 infiltrating ductal breast carcinomas

The emerging role of breast tomosynthesis

Identification of candidates for postmastectomy radiotherapy in patients with pT3N0M0 breast cancer

Sentinel lymph node biopsy in patients with breast cancer using superparamagnetic iron oxide and a magnetometer

Measuring of the maximum fat lesion ratio

Keynote webinar | Spotlight on antibody–drug conjugates in cancer